PURE BIOSCIENCE, INC. — fact timeline

PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2026 results: revenue $1,656,000, net income $1,873,000, EPS ($0.02).

“per share was ($0.01) for the fiscal third quarters ended April 30, 2026 and 2025, respectively. Summary of Results of Operations – Prior Nine Months ● Net product sales were $1,656,000 and $1,435,000 for the nine months ended April 30, 2026 and 2025, respectively. The $221,000 increase was attributable to higher sales across our end-user network. ● Net loss”

PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2026 results: revenue $506,000, net income $624,000, EPS ($0.01).

“) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2026. Summary of Results of Operations – Third Quarter ● Net product sales were $506,000 and $489,000 for the fiscal third quarters ended April 30, 2026 and 2025, respectively. The $17,000 increase was attributable to higher sales across our distribution network. ●”

PURE BIOSCIENCE, INC. issued 18,131,096 shares of common stock to accredited investors for $0.0553 per share.

“The Company raised $1.0 million in the Closing and issued an aggregate of 18,131,096 shares (collectively, the “Shares”) of the Company’s common stock at a purchase price of $0.0553 per share.”

PURE BIOSCIENCE, INC. entered into Securities Purchase Agreement with certain accredited investors valued at $1.0 million (effective 2026-04-30).

“ssued in the Private Placement Financing were issued pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into with the Investors.”

Darin Zehr was appointed as Director at PURE BIOSCIENCE, INC..

“On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.”

PURE BIOSCIENCE, INC. incurred convertible notes of $500,000 with certain accredited investors at 7.81%, compounded annually maturing the third-year anniversary of the date of issuance.

“On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).”

PURE BIOSCIENCE, INC. entered into Note Purchase Agreement with certain accredited investors valued at $500,000 (effective 2024-03-22).

“On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).”

PURE BIOSCIENCE, INC. reported the six months ended January 31, 2024 results: revenue $1,043,000, net income $1,737,000, EPS ($0.02) per share.

“Net product sales were $1,043,000 and $863,000 for the six months ended January 31, 2024 and 2023, respectively. The increase of $180,000 was attributable to increased sales across our end user and distribution network. ● Net loss for the six months ended January 31, 2024 was $1,737,000, compared to $2,053,000 for the six months ended January 31, 2023. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2024 was $1,593,000, compared to $1,842,000 for the six months ended January 31, 2023. ● Net loss per share was ($0.02) for the six months ended January 31, 2024 and 2023, respectively.”

PURE BIOSCIENCE, INC. reported the fiscal second quarter ended January 31, 2024 results: revenue $325,000, net income $1,002,000, EPS ($0.01) per share.

“Net product sales were $325,000 and $396,000 for the fiscal second quarter ended January 31, 2024 and 2023, respectively. The decrease of $71,000 was attributable to decreased sales across our end user network. ● Net loss for the fiscal second quarter ended January 31, 2024 was $1,002,000, compared to $1,060,000 for the fiscal second quarter ended January 31, 2023. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2024 was $938,000, compared to $993,000 for the fiscal second quarter ended January 31, 2023. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2024 and 2023, respectively.”

PURE BIOSCIENCE, INC. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 150,000,000 to 200,000,000 at the 2024-02-21 meeting.

“For Against Abstentions 61,666,543 2,226,172 314,817”

PURE BIOSCIENCE, INC. shareholders approved Adoption of the 2024 Equity Incentive Plan at the 2024-02-21 meeting.

“For Against Abstentions Broker Non-Votes 48,041,487 401,589 3,566,917 12,237,539”

PURE BIOSCIENCE, INC. shareholders approved Executive Compensation (non-binding advisory vote) at the 2024-02-21 meeting.

“For Against Abstentions Broker Non-Votes 48,049,734 412,190 3,548,069 12,237,539”

PURE BIOSCIENCE, INC. shareholders approved Ratification of Auditors at the 2024-02-21 meeting.

“For Against Abstentions 63,801,664 268,958 176,910”

PURE BIOSCIENCE, INC. shareholders approved Election of Directors at the 2024-02-21 meeting.

“Director For Withheld Broker Non-Votes Tom Y. Lee, CPA 51,623,453 386,540 12,237,539 Ivan Chen 51,598,411 411,582 12,237,539 Tom Myers 51,643,956 366,037 12,237,539 David M. Rendall 51,637,237 372,756 12,237,539 Robert Bartlett 51,667,737 342,256 12,237,539 Bernard Blotner 50,457,923 1,552,070 12,237,539”

PURE BIOSCIENCE, INC. reported financial results for fiscal year ended July 31, 2023.

“On October 30, 2023, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year ended July 30, 2023 and related information.”

PURE BIOSCIENCE, INC. incurred convertible notes of $1,015,000 at 7.55% maturing third-year anniversary of the date of issuance.

“On July 3, 2023, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $1,015,000 (the “Private Placement”).”

PURE BIOSCIENCE, INC. entered into Note Purchase Agreement with certain accredited investors valued at $1,015,000 (effective 2023-07-03).

“On July 3, 2023, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $1,015,000 (the “Private Placement”).”

PURE BIOSCIENCE, INC. reported the nine months ended April 30, 2023 results: revenue $1,269,000, net income $2,929,000, EPS ($0.03).

“Net product sales were $1,269,000 and $1,409,000 for the nine months ended April 30, 2023 and 2022, respectively.”

PURE BIOSCIENCE, INC. reported the fiscal third quarter ended April 30, 2023 results: revenue $406,000, net income $876,000, EPS ($0.01).

“Net product sales were $406,000 and $497,000 for the fiscal third quarters ended April 30, 2023 and 2022, respectively.”

Kristin A. Taylor resigned as Director at PURE BIOSCIENCE, INC..

“On March 19, 2023, Kristin A. Taylor delivered notice to the Board of her resignation from the Board, effective March 19, 2023.”

Tom Myers departed as Executive Vice President, Technology and Development at PURE BIOSCIENCE, INC..

“Tom Myers, the Company’s Chief Operating Officer and member of the Board, resigned as the Company’s Chief Operating Officer in connection with his transition to the Company’s Executive Vice President, Technology and Development, each effective as of the Effective Date.”

Robert Bartlett was appointed as President and Chief Executive Officer at PURE BIOSCIENCE, INC..

“the Board appointed Robert Bartlett, a member of the Board, as the Company’s President and Chief Executive Officer, effective as of the Effective Date.”

Tom Y. Lee resigned as President and Chief Executive Officer at PURE BIOSCIENCE, INC..

“Tom Y. Lee, the President, Chief Executive Officer and member of the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”), resigned as the Company’s President and Chief Executive Officer, effective as of the Effective Date.”

PURE BIOSCIENCE, INC. reported six months ended January 31, 2023 results: revenue $863,000, net income $2,053,000, EPS ($0.02).

“Six Months: Summary of Results of Operations ● Net product sales were $863,000 and $912,000 for the six months ended January 31, 2023 and 2022, respectively. The decrease of $49,000 was attributable to decreased sales across our transportation and distribution network. ● Net loss for the six months ended January 31, 2023 was $2,053,000, compared to $1,498,000 for the six months ended January 31, 2022. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2023 was $1,842,000, compared to $1,128,000 for the six months ended January 31, 2022. ● Net loss per share was ($0.02) for the six months ended January 31, 2023 and 2022, respectively.”

PURE BIOSCIENCE, INC. reported fiscal second quarter ended January 31, 2023 results: revenue $396,000, net income $1,060,000, EPS ($0.01).

“Q2: Summary of Results of Operations ● Net product sales were $396,000 and $415,000 for the fiscal second quarter ended January 31, 2023 and 2022, respectively. The decrease of $19,000 was attributable to decreased sales across our distribution network. ● Net loss for the fiscal second quarter ended January 31, 2023 was $1,060,000, compared to $702,000 for the fiscal second quarter ended January 31, 2022. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2023 was $933,000, compared to $522,000 for the fiscal second quarter ended January 31, 2022. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2023 and 2022, respectively.”

PURE BIOSCIENCE, INC. shareholders approved Advisory vote on the compensation of named executive officers (say-on-pay) at the 2023-02-08 meeting.

“(3) Executive Compensation. The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s named executive officers, with the approval of 96.84% of the votes cast, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal: For Against Abstentions Broker Non-Votes 49,699,924 1,617,819 2,905,322 11,742,927”

PURE BIOSCIENCE, INC. shareholders approved Ratification of the appointment of Weinberg & Company, P.A. as independent registered public accounting firm for fiscal year ending July 31, 2023 at the 2023-02-08 meeting.

“(2) Ratification of Auditors. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A., with the approval of 99.87% of the votes cast, as the Company’s independent registered public accounting firm for the fiscal year ending July 31, 2023. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal: For Against Abstentions 65,354,828 78,962 532,202”

PURE BIOSCIENCE, INC. shareholders approved Election of Directors at the 2023-02-08 meeting.

“(1) Election of Directors. The Company’s stockholders elected each of Tom Y. Lee, CPA, Ivan Chen, Tom Myers, Kristin A. Taylor, David M. Rendall, Robert Bartlett, and Bernard Blotner with the approval of 96.67%, 99.19%, 98.33%, 96.60%, 97.38%, 97.35% and 97.34%, of the votes cast, respectively, to hold office until next year’s Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following table shows the tabulation of the votes cast For and Withheld with respect to the election of each of the director nominees as well as the Broker Non-Votes submitted for each director nominee: Director For Withheld Broker Non-Votes Tom Y. Lee, CPA 52,417,512 1,805,553 11,742,927 Ivan Chen 53,783,287 439,778 11,742,927 Tom Myers 53,317,145 905,920 11,742,927 Kristin A. Taylor 52,377,326 1,845,739 11,742,927 David M. Rendall 52,804,580 1,418,485 11,742,927 Robert Bartlett 52,786,761 1,436,304 11,742,927 Bernard Blotner 52,782,415 1,440,650 11,742,927”

PURE BIOSCIENCE, INC. reported fiscal first quarter ended October 31, 2022 results: revenue $467,000, net income $993,000, EPS ($0.01).

“Net product sales were $467,000 and $497,000 for the fiscal first quarters ended October 31, 2022 and 2021, respectively.”

PURE BIOSCIENCE, INC. reported fiscal year ended July 31, 2022 results: revenue $1,813,000, net income ($3.5 million), EPS ($0.04).

“● Net product sales were $1,813,000 and $3,698,000 for the fiscal years ended July 31, 2022 and 2021, respectively. The decrease of $1,885,000 was attributable to decreased sales across our distribution and end-user network servicing the food processing, transportation, and janitorial industries. In addition, during the fiscal year ended July 31, 2022, we recognized $40,000 in royalties, compared to $229,000 in royalties for the fiscal year ended July 31, 2021. ● Net loss for the fiscal year ended July 31, 2022 was ($3.5 million), compared to ($2.3 million) for the fiscal year ended July 31, 2021. ● Net loss, excluding share-based compensation, for the fiscal year ended July 31, 2022 was ($2.9 million), compared to ($1.3 million) for the fiscal year ended July 31, 2021. ● Net loss per share was ($0.04) for the fiscal year ended July 31, 2022, compared to ($0.03) per share for the fiscal year ended July 31, 2021.”